HLJ1 is an endogenous Src inhibitor suppressing cancer progression through dual mechanisms

C. H. Chen, W. H. Chang, K. Y. Su, W. H. Ku, G. C. Chang, Q. S. Hong, Y. J. Hsiao, H. C. Chen, H. Y. Chen, R. Wu, P. C. Yang, J. J.W. Chen, S. L. Yu*

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

26 Scopus citations

Fingerprint

Dive into the research topics of 'HLJ1 is an endogenous Src inhibitor suppressing cancer progression through dual mechanisms'. Together they form a unique fingerprint.

Biochemistry, Genetics and Molecular Biology

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science